The Shotlee Journal
Browse Shotlee articles about Mounjaro.
Showing 9 / 801 Mounjaro articles
A spectacular backfire in Novo Nordisk's head-to-head trial against Eli Lilly's Mounjaro has widened the gap in the weight loss drug race, yet Ireland stands to gain from both giants. With billions in investments, thousands of jobs, and massive tax revenues, the Republic is placing an each-way bet on Wegovy and Mounjaro. This economic tie underscores pharma's pivotal role in Ireland's prosperity.
As GLP-1 drugs like Ozempic revolutionize obesity and diabetes care, muscle weakness emerges as a key challenge. Dr. Bob reveals why 47-65% discontinue treatment, patient perceptions vs. reality, and proven strategies like protein intake and strength training. Explore the next frontier in preserving muscle for long-term health.
Doctors publicly tout GLP-1 drugs like Ozempic for weight loss, but privately warn patients may need them lifelong. A systematic review of 48 studies reveals up to 60% weight regain after stopping. Here's how to use Ozempic as a kickstart and make weight loss permanent with lifestyle changes.
While AI hype focuses on drug discovery, Eli Lilly has quietly used it to supercharge manufacturing of its blockbuster GLP-1s, Zepbound and Mounjaro. This led to record production volumes that avoided FDA shortages and fueled massive revenue growth. Here's how they did it with digital twins and defect detection tech.
Deutsche Bank has reiterated its Buy rating on Eli Lilly stock, highlighting robust GLP-1 prescription growth despite recent dips. With Mounjaro and Zepbound leading, prescriptions rebounded 7% week-over-week, underscoring Lilly's dominance in the diabesity market. Discover the latest data on oral Wegovy and emerging oral GLP-1s like orforglipron.
Aspen Pharmacare Holdings Ltd. is aiming for regulatory approval of its copycat semaglutide version in Canada by September, positioning itself as a first-mover. CEO Stephen Saad shared this timeline in a recent interview, highlighting Canada's role as a benchmark for other nations. This development could enhance affordability of GLP-1 therapies like Ozempic.
Irish pharmaceutical exports hit a record €139bn in 2025, with GLP-1 weight-loss drugs from Eli Lilly and Novo Nordisk driving 20% of total goods exports. Eli Lilly's facilities in Ireland and massive US investments underscore the sector's growth. This boom promises faster access to innovative metabolic treatments for patients.
Novo Nordisk has received a second FDA untitled letter in weeks, this time targeting an Ozempic digital ad that parodies Apple's 'Get a Mac' campaign with actors Justin Long and John Hodgman. The regulator cites misleading presentations of Ozempic's indications and unsubstantiated superiority claims over other GLP-1s. Understand the concerns and what it means for patients seeking accurate information on these therapies.
A Rhode Island mother battled alcoholism for years, losing custody of her son, until GLP-1 drugs like Wegovy and Mounjaro helped curb her cravings in a pilot program. Gina Roberts shares her journey to two years sober, her own apartment, and family reunion. Addiction specialist Dr. Steven Klein discusses the promising role of these medications alongside traditional supports.
